Serum asymmetric dimethylarginine (ADMA), homocysteine, vitamin B 12, folate levels, and lipid profiles in epileptic children treated with valproic acid

European Journal of Pediatrics

Volumn 170, Issue 7, 2011, Pages 873-877

  Ozdemir, Ozlem ^a   Yakut, Ayten ^a   Dinleyici, Ener Cagri ^a   Aydogdu, Sultan Durmus ^a   Yarar, Coskun ^a   Colak, Omer ^a  

^a ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

Author keywords

ADMA; Asymmetric dimethylarginine; Epilepsy; Folate; Homocysteine; Valproic acid; Vitamin B12; VPA

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N(G),N(G) DIMETHYLARGININE; VALPROIC ACID;

ADOLESCENT; AMINO ACID BLOOD LEVEL; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; EPILEPSY; FEMALE; FOLIC ACID BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; MONOTHERAPY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEIZURE; TREATMENT DURATION; VITAMIN BLOOD LEVEL;

ADOLESCENT; ANTICONVULSANTS; ARGININE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CHOLESTEROL; CROSS-SECTIONAL STUDIES; DRUG ADMINISTRATION SCHEDULE; EPILEPSY; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; LIPIDS; MALE; TRIGLYCERIDES; VALPROIC ACID; VITAMIN B 12; VITAMIN B COMPLEX;

EID: 79959746732     PISSN: 03406199     EISSN: 14321076     Source Type: Journal    
DOI: 10.1007/s00431-010-1366-5     Document Type: Article

References (29)

1. Apeland T, Mansoor MA, Pentieva K et al (2002) The effect of B-vitamins on hyperhomocysteinemia in patients on antiepileptic drugs. Epilepsy Res 51:237-247 (Pubitemid 35238047)
2. Bleich S, Degner D, Sperling W et al (2004) Homocysteine as a neurotoxin in chronic alcoholism. Prog Neuropsychopharmacol Biol Psychiatry 28:453-464 (Pubitemid 38490756)
3. Böger RH, Bode-Böger SM, Szuba A et al (1998) Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 98:1842-1847 (Pubitemid 28509278)
4. Castro-Gago M, Novo-Rodríguez MI, Blanco-Barca MO et al (2006) Evolution of serum lipids and lipoprotein (a) levels in epileptic children treated with carbamazepine, valproic acid, and phenobarbital. J Child Neurol 21:48-53 (Pubitemid 43778765)
5. Clarke R, Daly L, Robinson K et al (1991) Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 324:1149-1155
6. Dinleyici EC, Kirel B, Alatas O et al (2006) Plasma total homocysteine levels in children with type 1 diabetes: relationship with vitamin status, methylene tetrahydrofolate reductase genotype, disease parameters and coronary risk factors. J Trop Pediatr 52:260-266 (Pubitemid 44304889)
7. Franzoni E, Govoni M, D"Addato S et al (1992) Total cholesterol, high-density lipoprotein cholesterol, and triglycerides in children receiving antiepileptic drugs. Epilepsia 33:932-935
8. Gidal BE, Tamura T, Hammer A, Vuong A (2005) Blood homocysteine, folate and vitamin B-12 concentrations in patients with epilepsy receiving lamotrigine or sodium valproate for initial monotherapy. Epilepsy Res 64:161-166 (Pubitemid 40853928)
9. Guerrini R (2006) Valproate as a mainstay of therapy for pediatric epilepsy. Paediatr Drugs 8:113-129
10. Karabiber H, Sonmezgoz E, Ozerol E et al (2003) Effects of valproate and carbamazepine on serum levels of homocysteine, vitamin B12 and folic acid. Brain Dev 25:113-115 (Pubitemid 36170307)
11. Karikas GA, Schulpis KH, Bartzeliotou A et al (2006) Lipids, lipoproteins, apolipoproteins, selected trace elements and minerals in the serum of children on valproic acid monotherapy. Basic Clin Pharmacol Toxicol 98:599-603
12. Kielstein JT, Böger RH, Bode-Böger SM et al (1999) Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 10:594-600 (Pubitemid 29117641)
13. Lentz SR, Rodinov NR, Sanjana D (2003) Hyperhomocysteinemia, endothelial dysfunction, and cardiovascular risk: the poteintial role of ADMA. Atheroscler 4:61-65 (Pubitemid 38234496)
14. Lipton SA, Kim WK, Choi YB et al (1997) Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc Natl Acad Sci USA 94:5923-5928
15. Malinow MR, Nieto FJ, Szklo M et al (1993) Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The Atherosclerosis Risk in Communities Study. Circulation 87:1107-1113 (Pubitemid 23110382)
16. Marangos PJ, Loftus T, Wiesner J et al (1990) Adenosinergic modulation of homocysteine-induced seizures in mice. Epilepsia 31:239-246 (Pubitemid 20181291)
17. Nygård O, Vollset SE, Refsum H et al (1995) Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 274:1526-1533
18. Ono H, Sakamoto A, Mizoguchi N, Sakura N (2002) The C677T mutation in the methylenetetrahydrofolate reductase gene contributes to hyperhomocysteinemia in patients taking anticonvulsants. Brain Dev 24:223-226 (Pubitemid 34553341)
19. Oz O, Gökçil Z, Bek S et al (2009) Is asymmetric dimethylarginine responsible for the vascular events in patients under antiepileptic drug treatment? Epilepsy Res 87:54-58
20. Reddy MN (1985) Effect of anticonvulsant drugs on plasma total cholesterol, high-density lipoprotein cholesterol and apolipoproteins A and B in children with epilepsy. Proc Soc Exp Biol Med 180:359-363
21. Robinson K, Mayer EL, Miller DP et al (1995) Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease. Circulation 92:2825-2830
22. Sener U, Zorlu Y, Karaguzel O et al (2006) Effects of common anti-epileptic drug monotherapy on serum levels of homocysteine, vitamin B12, folic acid and vitamin B6. Seizure 15:79-85 (Pubitemid 43192416)
23. Sozuer DT, Atakli D, Doǧu O et al (1997) Serum lipids in epileptic children treated with carbamazepine and valproate. Eur J Pediatr 156:565-567 (Pubitemid 27289859)
24. Surdacki A, Nowicki M, Sandmann J (1999) Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetrical dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 33:652-658 (Pubitemid 29164831)
25. Usui M, Matsuoka H, Miyazaki H et al (1998) Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci 62:2425-2430 (Pubitemid 28273149)
26. Valkonen VP, Päivä H, Salonen JT et al (2001) Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 358:2127-2128 (Pubitemid 34094905)
27. Vallance P, Leiper J (2004) Cardiovascular biology of the asymmetric dimethylarginine: dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol 24:1023-1030 (Pubitemid 38737826)
28. Vilaseca MA, Monrós E, Artuch R et al (2000) Anti-epileptic drug treatment in children: hyperhomocysteinaemia, B-vitamins and the 677C->T mutation of the methylenetetrahydrofolate reductase gene. Eur J Paediatr Neurol 4:269-277
29. Zoccali C, Bode-Böger S, Mallamaci F et al (2001) Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 358:2113-2117 (Pubitemid 34094901)